TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 30; p. v630
Main Authors Canale, M., De Luigi, N., Petracci, E., Delmonte, A., Ludovini, V., Dubini, A., Baglivo, S., Minenza, E., Chiadini, E., Landi, L., Papi, M., Bronte, G., Crinò, L., Ulivi, P.
Format Journal Article
LanguageEnglish
Published 01.10.2019
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1093/annonc/mdz260.056